2023
Classification, risk stratification and response assessment in myelodysplastic syndromes/neoplasms (MDS): A state-of-the-art report on behalf of the International Consortium for MDS (icMDS)
Stahl M, Bewersdorf J, Xie Z, Porta M, Komrokji R, Xu M, Abdel-Wahab O, Taylor J, Steensma D, Starczynowski D, Sekeres M, Sanz G, Sallman D, Roboz G, Platzbecker U, Patnaik M, Padron E, Odenike O, Nimer S, Nazha A, Majeti R, Loghavi S, Little R, List A, Kim T, Hourigan C, Hasserjian R, Halene S, Griffiths E, Gore S, Greenberg P, Figueroa M, Fenaux P, Efficace F, DeZern A, Daver N, Churpek J, Carraway H, Buckstein R, Brunner A, Boultwood J, Borate U, Bejar R, Bennett J, Wei A, Santini V, Savona M, Zeidan A. Classification, risk stratification and response assessment in myelodysplastic syndromes/neoplasms (MDS): A state-of-the-art report on behalf of the International Consortium for MDS (icMDS). Blood Reviews 2023, 62: 101128. PMID: 37704469, DOI: 10.1016/j.blre.2023.101128.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsInternational consensus classificationResponse assessmentWorld Health Organization classificationPatient-centered careRisk assessment toolClinical outcomesRisk stratificationOrganization classificationCentered careTherapeutic benefitTherapeutic outcomesConsensus classificationResponse criteriaInternational ConsortiumNeoplasmsLife assessmentAssessment toolOutcomesReportAssessmentPrognosticationCareMyelodysplastic Syndromes/Neoplasms—Insights Into Pathogenesis Leading to Improved Classification, Risk Stratification, and Treatments
Rose M, Zeidan A. Myelodysplastic Syndromes/Neoplasms—Insights Into Pathogenesis Leading to Improved Classification, Risk Stratification, and Treatments. The Cancer Journal 2023, 29: 109-110. PMID: 37195765, DOI: 10.1097/ppo.0000000000000663.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus Statements
2022
Prognostication in myelodysplastic syndromes (neoplasms): Molecular risk stratification finally coming of age
Xie Z, Chen E, Stahl M, Zeidan A. Prognostication in myelodysplastic syndromes (neoplasms): Molecular risk stratification finally coming of age. Blood Reviews 2022, 59: 101033. PMID: 36357283, DOI: 10.1016/j.blre.2022.101033.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsMyelodysplastic syndromePrognostic modelManagement of MDSInternational Prognostic Scoring SystemMolecular prognostic modelPrognostic scoring systemMolecular risk stratificationHeterogeneous clinical outcomesBone marrow failure disordersMarrow failure disordersRevised IPSSClinical outcomesRisk prognosticationRisk stratificationTraditional risk modelsScoring systemMDS pathobiologyPatient Preferences for Benefits, Risks, and Administration Route of Hypomethylating Agents in Myelodysplastic Syndromes
Zeidan AM, Tsai JH, Karimi M, Schmier J, Jayade S, Zormpas E, Hassan A, Ruiters D, Anthony C, Hill K, Wert T, Botteman M. Patient Preferences for Benefits, Risks, and Administration Route of Hypomethylating Agents in Myelodysplastic Syndromes. Clinical Lymphoma Myeloma & Leukemia 2022, 22: e853-e866. PMID: 35729009, DOI: 10.1016/j.clml.2022.04.023.Peer-Reviewed Original ResearchConceptsMyelodysplastic syndromePatient preferencesRelative attribute importanceRisk of AMLPatient advocacy group representativesAdministration burdenLevel of fatigueMode of administrationDCE choice tasksAML transformationMDS patientsSurvey patientsOral pillsCanadian patientsAdvocacy group representativesHypomethylating agentNumber of visitsAdministration frequencyAdministration routePatient proxyPatientsEquivalent effectivenessMDS riskAdministration methodsSame riskA phase 1b study of glasdegib + azacitidine in patients with untreated acute myeloid leukemia and higher-risk myelodysplastic syndromes
Sekeres MA, Schuster M, Joris M, Krauter J, Maertens J, Breems D, Gyan E, Kovacsovics T, Verma A, Vyas P, Wang ES, Ching K, O’Brien T, Gallo Stampino C, Ma WW, Kudla A, Chan G, Zeidan AM. A phase 1b study of glasdegib + azacitidine in patients with untreated acute myeloid leukemia and higher-risk myelodysplastic syndromes. Annals Of Hematology 2022, 101: 1689-1701. PMID: 35488900, DOI: 10.1007/s00277-022-04853-4.Peer-Reviewed Original ResearchConceptsAcute myeloid leukemiaHigh-risk myelodysplastic syndromePhase 1b studyChronic myelomonocytic leukemiaMyelodysplastic syndromeExpansion cohortSafety profileMDS cohortMyeloid leukemiaTreatment-emergent adverse eventsUntreated acute myeloid leukemiaNon-hematologic gradeMedian overall survivalAcceptable safety profileOverall response rateDrug-drug interactionsSafety cohortIntensive chemotherapyAdverse eventsOverall survivalClinical benefitQT prolongationAML cohortMyelomonocytic leukemiaGlasdegib
2019
Impact of Hydroxyurea on Survival and Risk of Thrombosis Among Older Patients With Essential Thrombocythemia.
Podoltsev NA, Zhu M, Zeidan AM, Wang R, Wang X, Davidoff AJ, Huntington SF, Giri S, Gore SD, Ma X. Impact of Hydroxyurea on Survival and Risk of Thrombosis Among Older Patients With Essential Thrombocythemia. Journal Of The National Comprehensive Cancer Network 2019, 17: 211-219. PMID: 30865915, DOI: 10.6004/jnccn.2018.7095.Peer-Reviewed Original ResearchConceptsImpact of hydroxyureaThrombotic eventsEssential thrombocythemiaEffect of hydroxyureaOlder patientsOverall survivalLower riskMultivariable Cox proportional hazards regression modelsCox proportional hazards regression modelHigh-risk essential thrombocythemiaProportional hazards regression modelsRetrospective cohort studyRisk of deathSEER-Medicare databaseHazards regression modelsRisk of thrombosisHU usersFrontline therapyCohort studyCurrent guidelinesStudy populationPatientsReal-world settingThrombosisOlder adults
2018
Performance of the Medical Research Council (MRC) and the Leukemia Research Foundation (LRF) score in predicting survival benefit with hypomethylating agent use in patients with relapsed or refractory acute myeloid leukemia
Stahl M, DeVeaux M, Montesinos P, Itzykson R, Ritchie EK, Sekeres MA, Barnard J, Podoltsev NA, Brunner A, Komrokji RS, Bhatt VR, Al-Kali A, Cluzeau T, Santini V, Roboz GJ, Fenaux P, Litzow M, Fathi AT, Perreault S, Kim TK, Prebet T, Vey N, Verma V, Germing U, Bergua J, Serrano J, Gore SD, Zeidan AM. Performance of the Medical Research Council (MRC) and the Leukemia Research Foundation (LRF) score in predicting survival benefit with hypomethylating agent use in patients with relapsed or refractory acute myeloid leukemia. Leukemia & Lymphoma 2018, 60: 246-249. PMID: 29963936, DOI: 10.1080/10428194.2018.1468893.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsDrug Resistance, NeoplasmFemaleHematopoietic Stem Cell TransplantationHumansLeukemia, Myeloid, AcuteMaleMiddle AgedNeoplasm Recurrence, LocalPrognosisRetrospective StudiesRisk AssessmentRisk FactorsSurvival AnalysisTransplantation, HomologousTreatment OutcomeYoung Adult
2017
Risk of myeloid neoplasms after radiotherapy among older women with localized breast cancer: A population-based study
Zeidan AM, Long JB, Wang R, Hu X, Yu JB, Huntington SF, Abel GA, Mougalian SS, Podoltsev NA, Gore SD, Gross CP, Ma X, Davidoff AJ. Risk of myeloid neoplasms after radiotherapy among older women with localized breast cancer: A population-based study. PLOS ONE 2017, 12: e0184747. PMID: 28902882, PMCID: PMC5597231, DOI: 10.1371/journal.pone.0184747.Peer-Reviewed Original ResearchConceptsBreast cancer survivorsMyeloid neoplasmsCancer survivorsBreast cancerOlder womenOlder breast cancer survivorsTherapy-related myeloid neoplasmsCompeting-risks survival analysisAbsolute risk increaseBenefits of radiotherapyPopulation-based studyAbsence of chemotherapyRisk of developmentMultiple sensitivity analysesEligible patientsSubsequent chemotherapyAdjuvant radiotherapyLocalized diseaseCumulative incidenceInitial treatmentSEER registryPoor outcomeTreatment recommendationsMedicare claimsMN diagnosisComparison of clinical outcomes and prognostic utility of risk stratification tools in patients with therapy-related vs de novo myelodysplastic syndromes: a report on behalf of the MDS Clinical Research Consortium
Zeidan AM, Al Ali N, Barnard J, Padron E, Lancet JE, Sekeres MA, Steensma DP, DeZern A, Roboz G, Jabbour E, Garcia-Manero G, List A, Komrokji R. Comparison of clinical outcomes and prognostic utility of risk stratification tools in patients with therapy-related vs de novo myelodysplastic syndromes: a report on behalf of the MDS Clinical Research Consortium. Leukemia 2017, 31: 1391-1397. PMID: 28111463, DOI: 10.1038/leu.2017.33.Peer-Reviewed Original ResearchConceptsInternational Prognostic Scoring SystemT-MDS patientsDe novo myelodysplastic syndromePrognostic scoring systemNovo myelodysplastic syndromeMyelodysplastic syndromeT-MDSClinical outcomesScoring systemMDS Clinical Research ConsortiumClinical Research ConsortiumRisk stratification toolRisk group categoriesRisk stratification modelConventional risk stratification modelPrognostic systemPrior therapyMedian survivalIndolent courseInferior survivalMDS patientsPrognostic utilityStratification toolWorse outcomesPatients
2016
Intensity of end‐of‐life care for patients with myelodysplastic syndromes: Findings from a large national database
Fletcher SA, Cronin AM, Zeidan AM, Odejide OO, Gore SD, Davidoff AJ, Steensma DP, Abel GA. Intensity of end‐of‐life care for patients with myelodysplastic syndromes: Findings from a large national database. Cancer 2016, 122: 1209-1215. PMID: 26914833, DOI: 10.1002/cncr.29913.Peer-Reviewed Original ResearchMeSH KeywordsAge FactorsAgedAged, 80 and overCause of DeathCritical IllnessDatabases, FactualFemaleHospice CareHumansIntensive Care UnitsLogistic ModelsMaleMultivariate AnalysisMyelodysplastic SyndromesOdds RatioPatient Care TeamQuality of Health CareRetrospective StudiesRisk AssessmentSEER ProgramSex FactorsSurvival AnalysisTerminal CareUnited StatesConceptsMyelodysplastic syndromeDays of lifeHospice enrollmentLife careEnd Results-Medicare databaseIntensive care unit admissionEOL quality measuresIntensity of endIntensity of EOLCare unit admissionTransfusion-dependent patientsLarge national databaseUnit admissionPalliative needsNonwhite patientsRed blood cellsMDS patientsPlatelet transfusionsHospice useEOL careHospice modelMultivariable modelLower oddsPatientsPopulation ages
2015
The evolving field of prognostication and risk stratification in MDS: Recent developments and future directions
Lee EJ, Podoltsev N, Gore SD, Zeidan AM. The evolving field of prognostication and risk stratification in MDS: Recent developments and future directions. Blood Reviews 2015, 30: 1-10. PMID: 26119927, DOI: 10.1016/j.blre.2015.06.004.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsMyelodysplastic syndromeRisk stratificationRecurrent molecular mutationsRisk stratification toolRelevant clinical outcomesPrediction of outcomeRisk/benefit calculationsClinical courseClinical outcomesStratification toolMDS patientsPrognostication toolsIndividual patientsClinical practiceMolecular testingTherapeutic interventionsPatient careTherapeutic selectionPatientsMolecular mutationsIndependent impactPrognosticationBiological heterogeneityOutcomesReliable assayEliminating Health Care Disparities With Mandatory Clinical Decision Support
Lau BD, Haider AH, Streiff MB, Lehmann CU, Kraus PS, Hobson DB, Kraenzlin FS, Zeidan AM, Pronovost PJ, Haut ER. Eliminating Health Care Disparities With Mandatory Clinical Decision Support. Medical Care 2015, 53: 18-24. PMID: 25373403, PMCID: PMC4262632, DOI: 10.1097/mlr.0000000000000251.Peer-Reviewed Original ResearchConceptsQuality improvement interventionsHealth care disparitiesVTE prophylaxis prescriptionProphylaxis prescriptionCare disparitiesImprovement interventionsCCDS toolsVTE prophylaxisWhite patientsRisk factorsVenous thromboembolism risk factorsClinical servicesComputerized clinical decision support toolRacial disparitiesHospitalized medical patientsRisk-appropriate prophylaxisVTE prophylaxis regimenAdult trauma patientsRetrospective cohort studyVTE risk factorsProportion of patientsThromboembolism risk factorsClinical decision support toolCompletion of checklistsPharmacological prophylaxis